BiotechTube
ARC Therapies

ARC Therapies

Tokyo, Japan· Est.

National Cancer Center Japan spin-out developing novel cell and gene therapies for oncology, with programs targeting ATLL and microbiome-based immunotherapies.

arctherapies.inc
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

AI Company Overview

National Cancer Center Japan spin-out developing novel cell and gene therapies for oncology, with programs targeting ATLL and microbiome-based immunotherapies.

Oncology

Technology Platform

Cell therapy platform leveraging National Cancer Center Japan's tumor immunology research, with programs in T-cell therapies and microbiome-based cancer immunotherapies.

Opportunities

Leveraging Japan's National Cancer Center research for first-in-class cell therapies, addressing Japan-endemic cancers like ATLL, and combining cell therapy with microbiome modulation for novel immunotherapies.

Risk Factors

Early-stage preclinical programs with unproven clinical efficacy, dependency on academic collaborations, and competition from established global cell therapy companies with more advanced platforms.

Competitive Landscape

Competes with global cell therapy leaders (Novartis, Gilead, BMS) and Japanese oncology biotechs; differentiates through National Cancer Center Japan research access and focus on Japan-specific oncology needs like ATLL.

More companies in Japan →